文章摘要
邓兰,廖堃,付琴,等.前列腺癌组织中泛素偶联酶 E2C、蛋白激酶 B表达及其与预后相关性[J].安徽医药,2022,26(10):1964-1968.
前列腺癌组织中泛素偶联酶 E2C、蛋白激酶 B表达及其与预后相关性
Expression of ubiquitin-conjugating enzyme E2C and protein kinase B in prostate cancer and its correlation with prognosis
  
DOI:10.3969/j.issn.1009-6469.2022.10.013
中文关键词: 前列腺肿瘤  泛素偶联酶 E2C  蛋白激酶 B  前列腺特异抗原  预后
英文关键词: Prostate tumor  Ubiquitin-conjugating enzyme E2C  Protein kinase B  Prostate-specific antigen  Prognosis
基金项目:
作者单位
邓兰 四川大学华西医院泌尿外科研究所泌尿外科四川成都 610041 
廖堃 四川大学华西医院泌尿外科研究所泌尿外科四川成都 610041 
付琴 四川大学华西医院泌尿外科研究所泌尿外科四川成都 610041 
徐苓傈 四川大学华西医院泌尿外科研究所泌尿外科四川成都 610041 
何其英 四川大学华西医院泌尿外科研究所泌尿外科四川成都 610041 
摘要点击次数: 745
全文下载次数: 316
中文摘要:
      目的探讨前列腺癌组织中泛素偶联酶 E2C(UBE2C)、蛋白激酶 B(AKT1)表达及其预后相关性。方法选取 2014年 1月至 2016年 12月四川大学华西医院泌尿外科研究所收集的 92例前列腺癌组织(前列腺癌组)、 70例良性前列腺增生组织(良性前列腺增生组)进行研究,根据随访结果将前列腺癌组分为两组,预后良好组( 68例)、预后不良组( 24例)。采用免疫组织化学法检测不同组织中 UBE2C、AKT1表达情况进行比较,并分析其与病人临床病理特征关系;采用 COX回归模型分析前列腺癌病人预后影响因素。结果与良性前列腺增生组相比,前列腺癌组 UBE2C[84.78%(78/92)比 22.86%(16/70)]、 AKT1[78.26%(72/92)比 28.57%(20/70)]阳性表达率均较高( P<0.05);前列腺癌组 UBE2C表达与年龄、 TNM分期、术前前列腺特异抗原(PSA)水平均无关( P>0.05),与 Gleason评分、淋巴结转移均有关( P<0.05)AKT1表达与年龄、淋巴结转移无关( P>0.05)与 Gleason评分、 TNM分期、术前 PSA水平均有关( P<0.05);与预后良好组相比,预,后不良组 UBE2C[100.00%(100/100)比 79.41%,(54/68)]、 AKT1[95.83%(23/100)比 72.06%(49/68)]阳性表达率均较高( P<0.05); COX回归模型分析结果显示, Gleason评分 ≥7分、 Ⅲ/Ⅳ期、伴淋巴结转移、术前 PSA水平 >10 μg/L、UBE2C高表达、 AKT1高表达均是影响前列腺癌病人预后状况的独立危险因素( P<0.05)。结论前列腺癌病人病灶组织 UBE2C、AKT1均为高表达,且与病人临床病理特征及预后状况密切相关,可能为评估病情及预后提供临床参考依据。
英文摘要:
      Objective To investigate the expression of ubiquitin-conjugating enzyme E2C (UBE2C) and protein kinase B (AKT1) in prostate cancer tissues and their correlation with prognosis.Methods A total of 92 cases of prostate cancer (prostate cancer group) and70 cases of benign prostate hyperplasia (benign prostate hyperplasia group) collected from January 2014 to December 2016 at the Insti.tute of Urology, West China Hospital, Sichuan University were selected for study. According to the follow-up results, the prostate cancergroup was divided into two groups, the good prognosis group (68 cases) and the poor prognosis group (24 cases). The expression ofUBE2C and AKT1 in different groups of tissues was detected by immunohistochemistry, and the relationship between them and the clin.icopathological characteristics of the patients was analyzed. The Cox regression model was used to analyze the prognostic factors of pros.tate cancer patients.Results Compared with the benign prostate hyperplasia group, the positive rates of UBE2C [84.78% (78/92) vs. 22.86% (16/70)] and AKT1 [78.26% (72/92) vs. 28.57% (20/70)] in the prostate cancer group were higher (P < 0.05). In prostate cancergroup, the expression of UBE2C was not related to age, tumor node metastasis (TNM) stage or preoperative prostate-specific antigen (PSA) level (P > 0.05) but was related to Gleason score and lymph node metastasis (P < 0.05). The expression of AKT1 in the prostate cancer group was not related to age or lymph node metastasis (P > 0.05), but was related to Gleason score, TNM stage and preoperative PSA level (P < 0.05). The positive rates of UBE2C [100.00% (100/100) vs. 79.41% (54/68)] and AKT1 [95.83% (23/100) vs. 72.06% (49/68)] in the poor prognosis group were higher than those in the good prognosis group (P < 0.05). The results of Cox regression modelanalysis showed that Gleason score ≥ 7, stage Ⅲ/Ⅳ, with lymph node metastasis, preoperative PSA level > 10 μg/L, and high expres.sion of UBE2C and AKT1 were all independent risk factors for the prognosis of patients with prostate cancer (P < 0.05).Conclusion UBE2C and AKT1 are highly expressed in the lesions of prostate cancer patients and are closely related to the clinicopathological char.acteristics and prognosis of patients, which may provide a clinical reference for the evaluation of the disease and prognosis.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮